MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.
about
Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Current challenges and novel treatment strategies in double hit lymphomasMYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical managementThe MYC/miR-17-92 axis in lymphoproliferative disorders: A common pathway with therapeutic potentialThe emerging role of Twist proteins in hematopoietic cells and hematological malignanciesc-MYC-miRNA circuitry: a central regulator of aggressive B-cell malignanciesNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewIntegrative systems medicine approaches to identify molecular targets in lymphoid malignanciesThe role of aberrant proteolysis in lymphomagenesisGenome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphomaPrognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximabDifferentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: the role of commonly used flow cytometry cell markers and the application of a multiparameter scoring systemThe copper chelator ATN-224 induces caspase-independent cell death in diffuse large B cell lymphomaCentral nervous system prophylaxis in diffuse large B-cell lymphoma.Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.Identification of predictive pathways for non-hodgkin lymphoma prognosisGray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France.Role of MYC in B Cell Lymphomagenesis.Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma.Cytoplasmic expression of C-MYC protein is associated with risk stratification of mantle cell lymphoma.Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.Epstein-Barr virus-induced gene 3 (EBI3): a novel diagnosis marker in Burkitt lymphoma and diffuse large B-cell lymphomaAnalysis of the coding genome of diffuse large B-cell lymphomaImmunohistochemical detection of MYC-driven diffuse large B-cell lymphomasMy treatment approach to patients with diffuse large B-cell lymphoma.Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantationThe pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomasC-MYC overexpression predicts aggressive transformation and a poor outcome in mucosa-associated lymphoid tissue lymphomasInhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphomaComplete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survivalComparative gene expression profiling identifies common molecular signatures of NF-κB activation in canine and human diffuse large B cell lymphoma (DLBCL).Identification of candidate B-lymphoma genes by cross-species gene expression profiling.Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphoma.C-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: a meta-analysis of epidemiological studiesAlisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2.Practice gaps and barriers to optimal care of hematologic malignancies in the United States.
P2860
Q24597424-468B7A9B-6107-4209-A9CB-2763F195F6E4Q26770385-2CD91D70-3FAF-42BB-97C8-DE340D7FB4F5Q26785379-875F9195-F497-4256-A696-D9BFD408BC9CQ26797469-6EBDFA00-D7C3-4F25-8073-FD8E604DA97AQ26822434-58DFC18C-E9AD-4F70-ACAA-4502A1B348CEQ26851373-3E0B3878-B27C-450D-B396-5AC37BFB92A4Q27304386-990EB0FE-153C-4433-8968-17BF7C3F8E40Q28067817-9D2DDAD4-898F-4E42-AECF-BC3FE16ABE1FQ28084404-54765351-6888-48FB-B163-BC58FC77F70DQ28248768-3ACD39B1-0BA9-4063-922C-3ED88547228AQ28256567-CB0B2CC0-14B4-449C-A4A8-E7850667822DQ28262278-A89C90A0-D063-46E3-B1A9-337F929A8880Q28389285-31FC1F69-118A-4A76-9D2F-BC074530EBD2Q30251550-69F09545-EAA6-4A1E-ACD7-454A5841E5C5Q30275206-9647961B-5C28-4809-8758-E644548F2B5DQ30497902-55547AA3-C855-40C6-A671-AE651D382325Q33560762-FB426552-5DAA-40AE-8FAC-5478F5206EBDQ33608499-3A82055C-1B6F-469E-9F81-5AE834CFBEEEQ33700531-527278CC-B167-48C5-8AD3-943A36A0E81BQ33802505-C8D20114-206A-4FF8-822D-5CAB833A575CQ33846801-136EAF08-742E-48D5-89C8-6FFA30AC720CQ34000188-475989CC-48A3-4F17-BE72-7FC5D6BC0619Q34023761-13A47C55-8911-4453-8FEB-BE84D47F9E89Q34205133-47DEB51E-0531-4E69-95E0-2730282E3CF2Q34236713-C4D48DE9-6C5D-4721-999B-4FF4E17C19D5Q34251964-19E8A61A-D42F-417C-8989-FF03E07658B0Q34325329-A65A2CF8-DEBC-48B9-958E-28379038D7E3Q34371078-2A713FA4-A8A4-42FD-B701-C1D767290242Q34371250-B2064433-14E3-43EC-A145-0F9AA1C1F2DDQ34860750-3AEA671B-F970-4E08-8272-AAD80168EFDAQ34882773-5AAA8751-7F9B-4F67-A3CA-162EB96B39C1Q34900634-5153B2E1-F999-46B3-A950-46783912B10FQ34918948-53A5BB7B-87F5-4BA4-9C59-F981DA683FBBQ34983966-21BB226D-7DDA-484E-80C2-D0B3EF21B29FQ35018604-E0669F3E-C8D2-4DCB-BCDB-A190C152A5EDQ35030096-7BF18794-5E6A-48DA-A453-53024B123A0BQ35051455-7FCB8CF3-5B81-4480-AFF0-54DDCEBCC30CQ35150618-4FB66099-ED49-4CC8-95B6-B05056B01040Q35180822-C18341A1-E823-444C-B82B-482E245C49AAQ35207616-F2905AFC-2B58-424C-ADB7-8DA5D003F23F
P2860
MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
MYC gene rearrangements are as ...... ated with R-CHOP chemotherapy.
@en
MYC gene rearrangements are as ...... ated with R-CHOP chemotherapy.
@nl
type
label
MYC gene rearrangements are as ...... ated with R-CHOP chemotherapy.
@en
MYC gene rearrangements are as ...... ated with R-CHOP chemotherapy.
@nl
prefLabel
MYC gene rearrangements are as ...... ated with R-CHOP chemotherapy.
@en
MYC gene rearrangements are as ...... ated with R-CHOP chemotherapy.
@nl
P2093
P1433
P1476
MYC gene rearrangements are as ...... ated with R-CHOP chemotherapy.
@en
P2093
Douglas E Horsman
Joseph M Connors
Kerry J Savage
Laurie H Sehn
Nathalie A Johnson
Susana Ben-Neriah
P304
P356
10.1182/BLOOD-2009-05-220095
P407
P577
2009-08-24T00:00:00Z